Vaxart Inc reports results for the quarter ended in March - Earnings Summary

Vaxart

13/05/2024 22:22

* Vaxart Inc  VXRT.OQ  reported a quarterly adjusted loss
of 14
cents​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -19
cents.  The mean expectation of three analysts for the quarter
was for a loss of 14 cents per share. Wall Street expected
results to range from -18 cents to -10 cents per share.
    * Revenue rose 223.1% to $2.18 million from a year ago;
analysts
expected $800.00 thousand. 
    * Vaxart Inc's reported EPS for the quarter was a loss of 14
cents​.
    * The company reported a quarterly loss of $24.42 million.
    * Vaxart Inc shares had fallen by 45.8% this quarter and
gained 23.1% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Vaxart Inc is
$5.00 
This summary was machine generated from LSEG data May 13 at
09:22 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.14          -0.14          Met
 Dec. 31 2023      -0.14          -0.12          Beat
 Sep. 30 2023      -0.18          -0.11          Beat
 Jun. 30 2023      -0.18          -0.16          Beat